Ceftriaxone
Third-Generation Cephalosporins
- Drug class
- Third-Generation Cephalosporins
- Availability
- Prescription only
- Routes
- Intravenous, Intramuscular
- Markets covered
- 3
- Products on record
- 57
Overview
Plain-language summary, compiled from the cited regulatory records
Ceftriaxone is an antibiotic medication belonging to the third-generation cephalosporin class of drugs [1]. It is used to treat various bacterial infections [1].
Before starting treatment with ceftriaxone, it is important to collect specimens to identify the bacteria causing the infection and to test their susceptibility to the drug [1]. Treatment can begin before the results of susceptibility testing are available [1]. To help prevent the development of drug-resistant bacteria and maintain the effectiveness of ceftriaxone, it should only be used to treat or prevent infections that are confirmed or strongly suspected to be caused by susceptible bacteria [1].
This medication is available under various brand names [1]. There were no adverse event reports for this drug in the last 12 months [2].
This is not medical advice. Consult a qualified healthcare professional.
Regulatory status by market
| Market | Regulator | Products | Last revision |
|---|---|---|---|
| GB United Kingdom | MHRA | 38 | May 29, 2026 |
| CA Canada | Health Canada | 16 | March 22, 2025 |
| US United States | FDA | 3 | January 22, 2026 |
GBUnited Kingdom· MHRA
38 products
Uses
4). Consideration should be given to official guidelines on the appropriate use of antibacterial agents.
How to take
CACanada· Health Canada
16 products
Uses
Ceftriaxone for Injection is indicated for the treatment of the following infections when caused by susceptible strains of the designated micro-organisms: • Lower Respiratory tract infections caused by E. coli, H. influenzae, K. pneumoniae and species, Staph.
aureus, Strep. pneumoniae and species (excluding enterococci). • Urinary tract infections (complicated and uncomplicated) caused by E. coli, Klebsiella species, P. mirabilis and P. vulgaris. • Bacterial Septicemia caused by E. coli, H. influenzae, K.
pneumoniae, Staph. aureus and Strep. pneumoniae, (excluding enterococci). • Skin and Skin Structure Infections caused by K. pneumoniae and species, P. mirabilis, Staph. aureus, Staph. epidermidis and Streptococcus species (excluding enterococci).
• Bone and Joint Infections caused by Staph. aureus, Strep. pneumoniae and Streptococcus species (excluding enterococci). coli and K. pneumoniae. • Meningitis caused by H. influenzae, N. meningitidis, and Strep. pneumoniae. Ceftriaxone sodium should not be used for the treatment of meningitis caused by L.
USUnited States· FDA
3 products
Uses
INDICATIONS AND USAGE
Before instituting treatment with ceftriaxone, appropriate specimens should be obtained for isolation of the causative organism and for determination of its susceptibility to the drug. Therapy may be instituted prior to obtaining results of susceptibility testing.
To reduce the development of drug-resistant bacteria and maintain the effectiveness of ceftriaxone for injection, USP and other antibacterial drugs, ceftriaxone for injection, USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria.
When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.
Ceftriaxone for injection, USP is indicated for the treatment of the following infections when caused by susceptible organisms: Lower Respiratory Tract Infections Caused by Streptococcus pneumoniae , Staphylococcus aureus, Haemophilus influenzae, Haemophilus parainfluenzae, Klebsiella pneumoniae, Escherichia coli, Enterobacter aerogenes, Proteus mirabilis or Serratia marcescens .
Drug interactions
Known interactions involving Ceftriaxone. Select one for details. This list is informational and not a complete interaction checker.
Showing 240 of 365. Type above to find a specific drug.
Interaction data compiled from DDInter (academic, CC-BY). Severity classification only - this is not a complete interaction checker and not medical advice.
Sources & citations
- [1]MHRA (UK) · PL269280005 · revised October 4, 2024
- [2]Health Canada (DPD) · 02289687 · revised March 22, 2025
- [3]FDA DailyMed · 03283208-8616-41… · revised January 19, 2026 [PDF]
Information on this page is compiled from public regulatory records. Drugvu is not affiliated with any regulator or pharmaceutical manufacturer. This is not medical advice. Always consult a qualified healthcare professional.